Company: SMNR
Filing Date: 2025-07-02
Form Type: CORRESP
Source: 0001193125-25-154943
Chunk: 0

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-07-02
Form: CORRESP
Chunk 0
---
Denali Capital Acquisition Corp. July 2, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attn: Franklin Wyman, Angela Connell, Jessica Dickerson, Joe McCann

| Re: | Denali Capital Acquisition Corp. |

Semnur Pharmaceuticals, Inc. Amendment No. 2 to Registration Statement on Form S-4 Filed June 11, 2025 File No. 333-283019 Ladies and Gentlemen: Denali Capital Acquisition Corp., a Cayman Islands exempted company (the “ Company”), files herewith Amendment No. 3 (“ Amendment No. 3”) to the above-referenced registration statement on Form S-4filed on November 6, 2024, as previously amended by Amendment No. 1 filed on April 21, 2025 and by Amendment No. 2 filed on June 11, 2025 (the “ Registration Statement”). Set forth below are the responses of the Company to the comments of the staff of the Division of Corporation Finance of the U.S. Securities and Exchange Commission (the “ Staff”) with respect to the Registration Statement contained in the Staff’s letter dated June 26, 2025 (the “ Comment Letter”). For ease of reference, each comment contained in the Comment Letter is printed below and is followed by the Company’s response. All page references in the responses set forth below refer to page numbers in Amendment No. 3. All capitalized terms used but not defined in this response letter have the meanings ascribed to such terms in Amendment No. 3. Amendment No. 2 to Registration Statement on Form S-4 Questions and Answers About the Business Combination and The Meeting What are the possible sources and the extent of dilution that public shareholders…, page 13

| 1. | The total share amounts presented in your tabular disclosure on page 14 differ from those presented on pages                                                                                                                                              
 iv, 61, 214 and 344. Further, your disclosure on page 14 includes certain items that will not result in shares outstanding after the Business Combination until the related options or warrants are exercised (e.g., shares underlying public and private 
 warrants and shares underlying Semnur options). Please revise to explain the basis for these differences and/or revise your presentations accordingly.                                                                                                    |

Response: The Company respectfully advises the Staff that the different tabular disclosure on pages 14